Shares of Exelixis (EXEL -6.4%
) are trading lower today following yesterday's post-session trading halt
, despite receiving approval from both the FDA and the European Medicines Agency for cabozantinib, a treatment for a rare type of thyroid cancer. Part of the reason for the dip can possibly be attributed to the lack of information
on the drug going into the decision, plus skittishness following an unexplained cancellation of the FDA's vote on cabozantinib's NDA earlier this month.